Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
- 20 March 2015
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (6), 523-532
- https://doi.org/10.1111/dom.12456
Abstract
More than 40 years after publication of the University Group Diabetes Program trial, the cardiovascular safety of sulphonylureas is still contentious. Although several hypotheses linking sulphonylureas to adverse cardiovascular effects exist, none provide conclusive evidence. Adding to the controversy, current clinical trials and observational studies provide inconsistent, and sometimes conflicting, evidence for the cardiovascular effects of sulphonylureas. Overall, observational evidence suggests that an increased risk of adverse cardiovascular outcomes is associated with sulphonylureas; however, these data may be subject to residual confounding and bias. Although evidence from randomized controlled trials has suggested a neutral effect, the majority of these studies were not specifically designed to assess the effect of sulphonylureas on adverse cardiovascular event risk. Current ongoing large clinical trials may provide some clarity on the cardiovascular safety of sulphonylureas, but the results are not expected for several years. With the continued uncertainties concerning the cardiovascular safety of all antidiabetic drugs, a clear answer with regard to sulphonylureas is warranted. The objectives of the present article were to provide an overview of the controversy surrounding sulphonylurea-related cardiovascular effects, to discuss the limitations of the current literature, and to provide recommendations for future studies aiming to elucidate the true relationship between sulphonylureas and adverse cardiovascular effects in people with type 2 diabetes.Funding Information
- Alberta Diabetes Institute
- Alliance for Canadian Health Outcomes Research in Diabetes (ACHORD) Strategic Training Program in Diabetic Research
- Izaak Walton Killam Memorial Scholarship
- Canadian Diabetes Association Doctoral Studentship
- Canada Research Chair from the Government of Canada
- Alberta Heritage Foundation for Medical Research
This publication has 95 references indexed in Scilit:
- Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation StudyAmerican Journal of Epidemiology, 2010
- Instrumental variable methods in comparative safety and effectiveness researchPharmacoepidemiology and Drug Safety, 2010
- Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studiesEuropean Journal of Epidemiology, 2010
- High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims DataEpidemiology, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of Internal Medicine, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Preconditioning: a paradigm shift in the biology of myocardial ischemiaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007